Pharsight

Ongentys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8907099 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
May, 2027

(3 years from now)

US8168793 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Apr, 2029

(5 years from now)

US9630955 NEUROCRINE Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
Dec, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550759 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Jul, 2026

(2 years from now)

US9745290 NEUROCRINE Dosage regimen for COMT inhibitors
Oct, 2027

(3 years from now)

US8524746 NEUROCRINE Dosage regimen for COMT inhibitors
Jul, 2029

(5 years from now)

US10071085 NEUROCRINE Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(6 years from now)

US10583130 NEUROCRINE Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(6 years from now)

US10357468 NEUROCRINE Medicaments for slowing Parkinson's disease
May, 2035

(11 years from now)

Ongentys is owned by Neurocrine.

Ongentys contains Opicapone.

Ongentys has a total of 9 drug patents out of which 0 drug patents have expired.

Ongentys was authorised for market use on 24 April, 2020.

Ongentys is available in capsule;oral dosage forms.

Ongentys can be used as method of treating parkinson's disease, method of inhibiting comt in the periphery; method of treating parkinson's disease; method of reducing o-methylation of l-dopa, adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease.

Drug patent challenges can be filed against Ongentys from 2024-04-24.

The generics of Ongentys are possible to be released after 27 May, 2035.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: 2024-04-24

Market Authorisation Date: 24 April, 2020

Treatment: Method of inhibiting comt in the periphery; Method of treating parkinson's disease; Method of reducing o-methylation of l-dopa; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's ...

Dosage: CAPSULE;ORAL

More Information on Dosage

ONGENTYS family patents

Family Patents